Infection Control Maintenance of Certification
Target Audience
This CME activity is intended for infectious diseases physicians, ID academicians, and internal medicine physicians.
Learning Objectives
At the conclusion of this activity, the learner will be able to:
- Identify and implement primary interventions for controlling an outbreak of methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Enterobacteriaceae (CRE), and C. difficile, in a healthcare facility.
- Recognize a Group A Streptococcus outbreak in a long-term care facility and implement an appropriate control measure.
- Recommend appropriate isolation precautions for TB.
- Know when post exposure prophylaxis is recommended for healthcare personnel exposed to selected infections.
- Recognize mumps and measles and initiate appropriate infection prevention measures.
- Utilize methods to determine the impact of an influenza pandemic on his/her hospital.
- Implement evidence-based strategies recommended by IDSA/SHEA to improve antibiotic use
Additional Information
Attachment | Size |
---|---|
Privacy and Use | 15.05 KB |
Normal Lab Values | 245.48 KB |
Faculty and Disclosures
Werner Bischoff, MD, Associate Professor of Medicine, Wake Forest Health Sciences; Research grants: CDC/DHHS
Timothy Jenkins, MD, Director, Antimicrobial Stewardship Program, Denver Health and Hospital Authority; Research grants: NIH/NIAID
Christopher Ohl, MD, Professor of Medicine, Wake Forest School of Medicine; Pfizer Pharmaceuticals: Advisory/Consultant role
Trish M. Perl, MD, Professor Medicine, Pathology and Epidemiology, The Johns Hopkins University; Pfizer Pharmaceuticals: Advisory/Consultant role; Research grants: Merck, Medimmune, CDC/VA
Melissa Schaefer, MD, Medical Officer, CDC; nothing to disclose
Edward Septimus, MD, Medical Director, Infection Prevention and Epidemiology, HCA, Inc.; 3M: Advisory/Consultant role; Sage Pharmaceuticals: Honoraria; Research grants: AHRQ, CDC, NIH
Pranita Tamma, MD, Director of Pediatric Antimicrobial Stewardship, The Johns Hopkins University; Research grants: Pfizer
David Weber, MD, Professor of Medicine, Pediatrics and Epidemiology, University of North Carolina; Clorox, Germitec, Pfizer, Merck, Johnson & Johnson: Advisory/ Consultant role; Research grants: CDC, NIH
Kathleen Matikonis, MA, IDSA Senior Education Officer; nothing to disclose
Accreditation Statement
IDSA is accredited by the Accreditation Council for Continuing Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
IDSA designates this enduring material for a maximum of 11 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to11 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Physician participation information will be shared with ABIM through ACCME PARS.
Available Credit
- 11.00 ABIM MOC II
- 11.00 AMA PRA Category 1 Credit(s)™